• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Directories » FDA Approved Drugs » Relpax (eletriptan hydrobromide)

AND
  • A
  • B
  • C
  • D
  • E
  • F
  • G
  • H
  • I
  • J
  • K
  • L
  • M
  • N
  • O
  • P
  • Q
  • R
  • S
  • T
  • U
  • V
  • W
  • X
  • Y
  • Z

Relpax (eletriptan hydrobromide)

  • Profile

Profile

Contact Information

Contact: Pfizer
Website: https://www.pfizer.com/

Currently Enrolling Trials

    Show More

    General Information

    Relpax (eletriptan hydrobromide), novel a triptan, relieves pain in nerve endings and associated symptoms caused by migraine headaches.

    Mechanism of Action

    Relpax is a selective 5-hydroxytryptamine 1B/1D (5-HT1B/1D) receptor agonist that acts at serotonin 5HT1B receptors on intracranial blood vessels and 5HT1D receptors on sensory nerve endings to relieve the pain and associated symptoms of a migraine attack.

    Side Effects

    Adverse events associated with the use of Relpax may include, but are not limited to, the following:

    • Fatigue
    • Somnolence
    • Nausea
    • Dizziness

    Dosing/Administration

    Relpax was shown to be effective at doses of 20 mg, 40 mg and 80 mg. The maximum recommended single dose of Relpax is 40 mg.

    Relpax should not be used by patients with severe hepatic impairment. Relpax tablets should not be used within at least 72 hours with potent CYP3A4 inhibitors.

    Clinical Trial Results

    Approval for Replax was based on 10 randomized, double-blind clinical studies. More than 9,000 patients participated in the clinical trials and more than 70,000 migraine attacks were treated.

    Relpax was effective in relieving migraine pain and the associated symptoms of nausea and sensitivity to light and sound. The drug has a rapid onset of action (as early as 30 minutes), superior efficacy and a lower headache recurrence rate than those reported for other triptans.

    Additional Information

    For additional information on Relpax, please contact website the Pfizer website.

    For information on Migraine Headaches, visit The National Headache Foundation

    Approval Date: 2002-12-01
    Company Name: Pfizer
    Back to Listings

    Upcoming Events

    • 16Feb

      Fundamentals of FDA Inspection Management: Reduce Anxiety, Increase Inspection Success

    • 21May

      WCG MAGI Clinical Research Conference – 2023 East

    Featured Products

    • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

      Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    • Surviving an FDA GCP Inspection

      Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

    Featured Stories

    • SurveywBlueBackground-360x240.png

      Sites Name Tech Acceptance as Essential Factor in Selection of Sponsors, Survey Finds

    • TrendsInsights2023-360x240.png

      WCG Clinical Research Trends and Insights for 2023, Part Two

    • TimeMoneyEffort-360x240.png

      Time is Money and So Is Effort, Budgeting Experts Say

    • TrendsInsights2023A-360x240.png

      WCG Clinical Research Trends and Insights for 2023, Part Three

    Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

    The information you need to adapt your monitoring plan to changing times.

    Learn More Here
    • About Us
    • Contact Us
    • Privacy Policy
    • Do Not Sell or Share My Data

    Footer Logo

    300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

    Phone 617.948.5100 – Toll free 866.219.3440

    Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing